

Villepinte, 1st August 2013

AVAILABILITY OF GUERBET'S 2013 HALF-YEARLY FINANCIAL REPORT

Guerbet announces the availability to the public and the filing of its Half-Yearly Financial Report with the French Autorité des marchés financiers (AMF).

This document is available on Guerbet's website at **www.guerbet.com** in Investors – Documents section.

About Guerbet

A pioneer in the field of contrast agents with more than 80 years of experience, Guerbet is the only pharmaceutical group fully dedicated to medical imaging worldwide. As such it has a complete offering of contrast products for X-Ray and MRI and for interventional radiology, along with a range of injectors and related medical equipment to provide improved diagnosis and treatment of patients.

To promote the discovery of new products and assure its future growth, Guerbet devotes significant resources to research and development every year (approximately 10% of sales). Guerbet (GBT) is listed on NYSE Euronext Paris (Eurolist Segment B – Mid Caps) and had sales of €403 million in 2012 with a total workforce of 1,400 employees including 1,000 in France.

Guerbet is a member of G5 Health, the industry association that brings together major French health and life sciences companies.

For additional information about Guerbet, please consult: www.guerbet.com

Contact: CFO Department - Tel. : +33 (0)1 45 91 50 69